Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14)+

Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14)+

Abstract: The prognosis for multiple myeloma (MM) has continued to improve with the development of a series of novel molecular targeted drugs over time. However, the prognosis remains poor for cases with high-risk chromosomal abnormalities. Of such abnormalities, t(4;14) is the second most common, o...

Full description

Saved in:
Bibliographic Details
Main Authors: Sae Matsuoka, Naoki Osada, Hirokazu Kubota, Ko Kikuzato, Hiroo Koyama, Takeshi Sonoda, Akiko Idei, Minoru Yoshida, Masaki Kikuchi, Takashi Umehara, Chiduru Watanabe, Teruki Honma, Hiroshi Yasui, Sho Ikeda, Naoto Takahashi, Hideki Nakasone, Jiro Kikuchi, Yusuke Furukawa
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Blood Neoplasia
Online Access:http://www.sciencedirect.com/science/article/pii/S2950328025000263
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items